Pharus Sicav Medical Innovation
| Net Asset Value | 129,01 EUR |
|---|---|
| Fund Size | 1.468.406 EUR |
| Launch Date | 2 ott 2012 |
| Benchmark | BENCHMARK COMPOSITE 17389 |
| Sicav | PHARUS SICAV |
|---|---|
| Management Company | PHARUS MANAGEMENT LUX SA |
| Investment Manager | Pharus Asset Management SA |
Risk & reward profile
- 1
- 2
- 3
- 4
- 5
- 6
- 7
Performance was driven by the US healthcare sector, supported by a landmark clinical breakthrough: the successful Phase 3 INTerpath-001 trial of the personalised mRNA cancer vaccine mRNA-4157/V940, developed in combination with Merck’s Keytruda. The announcement triggered an exceptional rally in the stocks involved, with Moderna surging by more than 100% intraday, validating its oncology pipeline, while Merck & Co. also performed strongly. Both companies were the leading positive contributors during the month. Conversely, CVS Health and UnitedHealth were among the weakest contributors.
We believe that the sector, which has risen since the beginning of the year, can maintain its current momentum. The portfolio is focused on leading global healthcare companies trading at discounted valuations.
Last updated on 10.09.2026
| Euro Fx Curr Fut Sep26 | 82.63 % |
|---|---|
| Moderna Inc | 6.39 % |
| Eli Lilly & Co | 4.93 % |
| Merck & Co. Inc. | 4.87 % |
| Amgen Inc | 4.16 % |
| Vertex Pharmaceuticals Inc | 4.03 % |
| Abbvie Inc | 3.65 % |
| Iqvia Holdings Inc | 3.57 % |
| Pfizer Inc | 3.53 % |
| Centene Corp | 3.48 % |
SFDR Article: 8
The Sub-Fund does not have as its objective a sustainable investment, but promotes social characteristics with a proportion of sustainable investments with a social objective of at least 80% of its assets.
Objectives
The Sub-Fund’s sustainable investment objective is to select companies promoting peaceful, just and inclusive principles, evidencing a strong Sustainability rating and following good governance practices, while avoids the exposure to companies involved in controversial weapons production, tobacco production, adult entertainment, gambling sector, violation of United Nation Global Pact, as per the internal ESG policy defined.
Social characteristics promoted are mainly represented by the below:
- Security of products and health
- Human rights and human dignity
- Equality labour conditions
- Governance
Asset Allocation
All the investments are assessed ex ante by an independent external ESG advisor and need to be compliant with including criteria and not in breach with excluding criteria set out on the applicable ESG policy. Investments aligned with E/S characteristic must attain the social characteristics promoted by the financial product and must represent at least 80% of the Sub-fund’s asset. Sustainable investments are investments in securities whose rating is considered acceptable and which comply with the excluding criteria set out in the ESG policy applicable. Other Investments include cash, derivatives, bonds and equities which do not have any ESG rating or with a weak ESG rating and can represent up to 20% of the portfolio.
Principal adverse impacts
This financial product considers PAI and monitors additional PAI with the support of an ESG Advisor that produces, on quarterly basis, a complete report that illustrates the PAI and the results for the portfolio. Furthermore, the Sub-Fund focuses on the PAI number 10 and 11. PAI number 10 monitors/takes into consideration weight of company with severe violation of UNGC principles or OECD guidelines for multinationals. PAI number 11 refers to weight of companies without mechanism for monitoring the compliance with UNGC principles and OECD guidelines.
Binding elements
The exclusion criteria applied to the investment universe, are aimed to exclude companies
31.03.2025